Literature DB >> 93874

Myelin basic protein treatment of experimental allergic encephalomyelitis in monkeys.

E C Alvord, C M Shaw, S Hruby.   

Abstract

Treatment of experimental allergic encephalomyelitis (EAE) in two strains of monkeys with large amounts of myelin basic basic protein (BP) fails unless an adjunct is also used. In both strains the adjunct by itself is more effective than BP by itself, but in the one strain which could be investigated sufficiently, the combination can be made almost totally effective in reversing EAE. The adjunct varies with the strain of monkey, an antibiotic in Macaca mulatta and a steroid in Macaca fascicularis. Similar adjunctive treatments should be considered in the management of multiple sclerosis, for EAE remains one of the best studied models.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 93874     DOI: 10.1002/ana.410060603

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

1.  Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.

Authors:  S D Sharma; B Nag; X M Su; D Green; E Spack; B R Clark; S Sriram
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

2.  Treatment of experimental allergic encephalomyelitis with myelin basic protein: which route is best?

Authors:  S Levine; R Sowinski
Journal:  Neurochem Res       Date:  1984-10       Impact factor: 3.996

3.  Experimental allergic encephalomyelitis in the monkey: humoral immunity and blood-brain barrier function.

Authors:  P Gallo; D Cupic; F Bracco; L Krzalic; B Tavolato; L Battistin
Journal:  Ital J Neurol Sci       Date:  1989-12

4.  Experimental allergic encephalomyelitis in cynomolgus monkeys. Quantitation of T cell responses in peripheral blood.

Authors:  L Massacesi; N Joshi; D Lee-Parritz; A Rombos; N L Letvin; S L Hauser
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 5.  Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review.

Authors:  V K Tuohy
Journal:  Neurochem Res       Date:  1994-08       Impact factor: 3.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.